Find in Library

<p>Abstract</p> <p>Background</p> <p>Melanoma antigen D1 (MAGED1) is a member of the type II melanoma antigen (MAGE) family. The down-regulation of MAGED1 expression has been shown in breast carcinoma cell lines and in glioma stem cells and may play an important role in apoptosis and anti-tumorigenesis. However, there is no report on its clinical role in colorectal cancer (CRC).</p> <p>Methods</p> <p>We examined the expression of MAGED1 by qPCR in colorectal cancer tissues and their adjacent non-tumorous tissues taken from 6 cases and performed Western blotting and IHC analyses. In addition, we analyzed MAGED1 expression in 285 clinicopathologically characterized colorectal cancer patients.</p> <p>Results</p> <p>MAGED1 expression was significantly down-regulated in colorectal cancer tissues compared with adjacent non-tumorous tissues and was associated with clinical stage (<it>p</it> < 0.001), T classification (<it>p</it> = 0.001), N classification (<it>p</it> < 0.001), M classification (<it>p</it> < 0.001) and pathologic differentiation (<it>p</it> = 0.002). Patients with lower MAGED1 expression had a shorter survival time than those with higher MAGED1 expression. Univariate and multivariate analyses indicated that MAGED1 expression was an independent prognostic factors (<it>p</it> < 0.001).</p> <p>Conclusions</p> <p>MAGED1 may serve as a novel prognostic biomarker of human colorectal cancer.</p>